A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan clinical oncology group study (JCOG1203)

Gynecologic Cancer Study Group of the Japan Clinical Oncology Group

Research output: Contribution to journalComment/debatepeer-review

14 Citations (Scopus)

Abstract

Fertility-sparing treatment has been accepted as a standard treatment for epithelial ovarian cancer in stage IA non-clear cell histology grade 1/grade 2. In order to expand an indication of fertility-sparing treatment, we have started a non-randomized confirmatory trial for stage IA clear cell histology and stage IC unilateral non-clear cell histology grade 1/grade 2. The protocol-defined fertility-sparing surgery is optimal staging laparotomy including unilateral salpingo-oophorectomy, omentectomy, peritoneal cytology and pelvic and para-aortic lymph node dissection or biopsy. After fertilitysparing surgery, four to six cycles of adjuvant chemotherapy with paclitaxel and carboplatin are administered. We plan to enroll 250 patients with an indication of fertility-sparing surgery, and then the primary analysis is to be conducted for 63 operated patients with pathologically confirmed stage IA clear cell histology and stage IC unilateral non-clear cell histology grade 1/grade 2. The primary endpoint is 5-year overall survival. Secondary endpoints are other survival endpoints and factors related to reproduction. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000013380.

Original languageEnglish
Pages (from-to)595-599
Number of pages5
JournalJapanese journal of clinical oncology
Volume45
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Keywords

  • Early stage
  • Fertility-sparing surgery
  • Gynecol-surg
  • Gynecology
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan clinical oncology group study (JCOG1203)'. Together they form a unique fingerprint.

Cite this